Novel influenza A (H1N1) is a new flu virus of swine origin that was first detected in Mexico and the United States in March and April, 2009. The first novel H1N1 patient in the United States was confirmed by laboratory testing at CDC on April 15, 2009. The second patient was confirmed on April 17, 2009. It was quickly determined that the virus was spreading from person-to-person. On April 22, CDC activated its Emergency Operations Center to better coordinate the public health response. On April 26, 2009, the United States Government declared a public health emergency.
It’s thought that novel influenza A (H1N1) flu spreads in the same way that regular seasonal influenza viruses spread; mainly through the coughs and sneezes of people who are sick with the virus.
CureVac GmbH, a clinical stage biopharmaceutical company developing a new class of therapies and vaccines based on mRNA, and the German Federal Research Institute for Animal Health, Friedrich-Loeffler-Institute (FLI), Germany, today announced that mRNA vaccines (RNActive) based on the company's RNA technology platform have the potential to provide effective protection against infectious diseases.
BioCryst Pharmaceuticals, Inc. announced completion of the planned interim analysis of the peramivir Phase 3 trial in patients admitted to the hospital with serious influenza. The difference between peramivir and control groups for the primary endpoint was small and the recalculated sample size was greater than the predefined futility boundary of 320 subjects. Based on this information, the independent data monitoring committee (DMC) recommended that the study be terminated for futility.
In 2009, a new strain of influenza, or flu, virus emerged and spread rapidly to many countries around the world. It was declared a pandemic by the World Health Organization (WHO) in June 2009.
CEL-SCI Corporation announced today that an interim review of the safety data from its open label, randomized, controlled, pivotal Phase III study of Multikine (Leukocyte Interleukin, Injection) investigational immunotherapy by an Independent Data Monitoring Committee (IDMC) raised no safety concerns.
Sanofi Pasteur, the vaccines division of Sanofi, presented today an overview of Phase II and Phase III clinical trials for its investigational quadrivalent influenza vaccine (QIV).
A new model of influenza transmission, published in BioMed Central's open access journal BMC Medicine, using more detailed information about patterns and severity of infection than previous models, finds that cases and transmission rates of H1N1 during the 2009-2010 flu pandemic have been underestimated. This model can provide a more robust and accurate real-time estimate of infection during a pandemic, which will help health services prepare and respond to future outbreaks.
With cold and flu season upon us, many companies have geared up for what is predicted to be a busy flu season producing 150 million doses of the influenza vaccine, up 17 million from last year.
Mathematicians have developed a powerful tool to quantify the spread and infectiousness of viruses like the pandemic H1N1 flu strain, which can be used together with modern laboratory techniques to help the healthcare system plan its response to disease outbreaks.
The identification of the virus responsible for a second case of SARS-like respiratory virus, "London1_novel CoV 2012", has raised concerns over the risk of the disease spreading. These concerns may be justified given the observed rise in virus's genomic Replikin Count.
With flu season just around the corner, Fresenius Medical Care North America (FMCNA), the nation's leading network of dialysis facilities, is urging dialysis patients to get flu shots to protect themselves against this common infectious disease. In October, FMCNA will begin offering at no cost to all of its dialysis patients and staff, flu vaccinations, which protect against both seasonal flu and H1N1 swine flu.
A new international survey published in The Lancet Infectious Diseases has revealed that during the H1N1 influenza pandemic in 2009, people in Britain lagged far behind other countries in adopting protective behaviours, such as increasing their practice of covering their mouth with a tissue when sneezing or coughing.
NanoViricides, Inc. reported today that its oral FluCide drug candidates demonstrated dramatically improved survival in animals administered a lethal dose of the H3N2 influenza A virus.
Many U.S. schools are not prepared for bioterrorism attacks, outbreaks of emerging infectious diseases or pandemics, despite the recent 2009 H1N1 influenza pandemic that resulted in more than 18,000 deaths worldwide, Saint Louis University researchers say.
University Hospitals Case Medical Center clinical researchers will present findings about a one-two punch to prevent colds and flu in San Francisco at the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) on Sept. 9.
A team of engineers and students at the University of Rhode Island has developed an advanced blood-testing technology that incorporates a smartphone application, a hand-held biosensor and a credit card-sized cartridge to provide rapid, accurate biological analysis and wireless communication of test results.
NanoViricides, Inc. announced today that anti-influenza drug candidates under its FluCide program, when given orally, led to strong antiviral antibody response. The antibody response with Oral administration was stronger than that with IV administration and was substantially greater than that observed with oseltamivir.
Less than half of U.S. schools address pandemic preparedness in their school plan, and only 40 percent have updated their school plan since the 2009 H1N1 pandemic, according to a study published in the September issue of the American Journal of Infection Control, the official publication of the Association for Professionals in Infection Control and Epidemiology (APIC).
NanoViricides, Inc. announced today that anti-influenza drug candidates under its FluCide program, when given orally, were nearly as effective as when administered as IV injections in terms of reduction in lung viral load.
The Infectious Disease Research Institute (IDRI), a Seattle-based non-profit research organization that is a leading developer of adjuvants used in vaccines combating infectious disease, and Medicago Inc., a biopharmaceutical company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), announce that they have been cleared by the U.S. Food and Drug Administration (FDA) to initiate a Phase 1 clinical trial for an H5N1 Avian Influenza VLP vaccine candidate.
The U.S. Food and Drug Administration announced today that it has approved the 2012-2013 influenza (flu) vaccine formulation for all six manufacturers licensed to produce and distribute the vaccines in the United States.
Terms
While we only use edited and approved content for Azthena
answers, it may on occasions provide incorrect responses.
Please confirm any data provided with the related suppliers or
authors. We do not provide medical advice, if you search for
medical information you must always consult a medical
professional before acting on any information provided.
Your questions, but not your email details will be shared with
OpenAI and retained for 30 days in accordance with their
privacy principles.
Please do not ask questions that use sensitive or confidential
information.
Read the full Terms & Conditions.